PARP inhibitors as therapy for small cell lung carcinoma: A systematic review and meta-analysis of clinical trials

PARP inhibitors as therapy for small cell lung carcinoma: A systematic review and meta-analysis of clinical trials

Background: Small Cell Lung Cancer (SCLC) is a neuroendocrine carcinoma characterized by aggressive behavior and poor prognosis with limited treatment options. Poly ADP-Ribose Polymerase inhibitors (PARPi) are novel anti-cancer agents that induce DNA damages and cause cell death in tumor cells with...

Full description

Saved in:
Bibliographic Details
Main Authors: Samuel Pratama, Lowilius Wiyono, Martien Silviandy Setiawan, Brigitta Cindy Lauren
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Cancer Treatment and Research Communications
Subjects:
PARPi
Small-cell lung cancer
Efficacy
Adverse event
Online Access:http://www.sciencedirect.com/science/article/pii/S2468294225000127
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items